Schizophrenia and platelet monoamine oxidase: research strategies.
The most widely replicated neurochemical finding in schizophrenia is that of lower levels of monoamine oxidase (MAO) in the platelets of chronic schizophrenics than in normal controls. Yet, the etiological role of MAO in schizophrenia remains to be demonstrated. The incidence of low MAO in other psychiatric disorders, effects of diet, hormones and drugs, and relationships of platelet MAO to brain levels and genetic mechanisms remain unclear. This article examines factors which make any biological indicator suitable for use as a diagnostic test for schizophrenia and inquires into the methodological pitfalls and unexamined assumptions of various research strategies which use this measure.
D000367:Age Factors; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000201:enzymology; D001792:Blood Platelets / Q000201:enzymology*; D004347:Drug Interactions; D005247:Feeding Behavior; D006728:Hormones / Q000097:blood; D006801:Humans; D008995:Monoamine Oxidase / Q000097:blood* / Q000235:genetics; D010375:Pedigree; D012107:Research Design; D012559:Schizophrenia / Q000201:enzymology*; D012565:Schizophrenic Psychology; D009435:Synaptic Transmission
D014150:Antipsychotic Agents; D006728:Hormones; D008995:Monoamine Oxidase